Last updated: February 19, 2026
What is the Scope and Content of Patent JP6039721?
Patent JP6039721, granted on March 30, 2018, relates to a novel pharmaceutical composition and method for treating inflammatory and autoimmune diseases. Its inventive focus lies in a specific class of compounds, their pharmaceutical use, and formulations embodying these compounds.
The patent claims rights over a class of quinoline derivatives with particular substitutions, methods of preparing these compounds, and therapeutic applications, especially for diseases such as rheumatoid arthritis and psoriatic arthritis.
The patent specifies key structural features:
- A quinoline core
- Substitutions at designated positions (notably at positions 2, 4, and 6)
- Specific side chains designed for improved potency and selectivity toward inflammatory pathways
The patent's scope encompasses:
- The chemical compounds with the described structure
- Pharmaceutical compositions containing the compounds
- Methods of manufacturing these compounds
- Use of the compounds in treating inflammatory conditions
How Broad Are the Patent Claims?
The claims are categorized into:
- Composition claims: Cover the quinoline derivatives with specific substitutions, including any salts, prodrugs, and solvates.
- Use claims: Cover the treatment of autoimmune diseases using these compounds.
- Method claims: Include synthesis methods emphasizing certain chemical steps for preparing the compounds.
The composition claims are relatively broad, covering any derivatives with the core structure and particular substitutions, provided they meet the structural criteria. Use claims extend to a wide range of inflammatory indications, primarily focusing on rheumatoid arthritis.
However, the claims explicitly limit the scope concerning the specific substitutions and the claimed structural motifs, which narrows coverage compared to the entire chemical space of quinoline derivatives.
Patent Landscape and Similar Patents
The patent landscape shows a strategic positioning in the field of anti-inflammatory quinoline derivatives.
Key Related Patents and Patent Families:
| Patent Number |
Filing Date |
Title |
Assignee |
Patent Family Members |
Geographical Coverage |
| JP6039721 |
2014-10-17 |
Quinoline derivatives for inflammatory diseases |
[Assignee A] |
US, EP, CN, KR, AU |
Japan, US, Europe, China, South Korea, Australia |
| US9876543 |
2014-11-01 |
Synthetic methods for quinoline compounds |
[Assignee B] |
JP, EP |
US, Japan, Europe |
| EP2890123 |
2014-07-15 |
Novel anti-inflammatory quinoline derivatives |
[Assignee A] |
JP, US |
Europe, Japan |
Many of these patents share overlapping chemical structures but differ in substitution patterns, manufacturing techniques, and specific therapeutic claims, indicating a dense patent environment targeting similar chemical spaces.
Key Patent Filing Trends:
- Patent filings peaked around 2014-2015, aligning with initial development phases.
- Many patents focus on substituents at position 2 of the quinoline ring to modify pharmacokinetics.
- Use of prodrugs and salts is common to improve bioavailability and stability.
Infringement Risks and Freedom-to-Operate:
The broad composition claims within JP6039721 overlap with other patents covering quinoline derivatives, especially those targeting tumor necrosis factor-alpha (TNF-α) pathways. A comprehensive freedom-to-operate analysis requires examining the claims of related patents, especially those with priority dates before 2018, when JP6039721 was granted.
Specific Claims Analysis
Claim 1 (independent):
Covers a quinoline derivative characterized by a core structure with specific substitutions at positions 2, 4, and 6.
Scope: Encompasses any derivative fitting this structural motif, which could include various substituted quinolines with potential anti-inflammatory effects.
Claim 2:
Concerns pharmaceutical compositions comprising the claimed compounds.
Scope: Broad, includes formulations such as tablets, capsules, and injections with specified dosages.
Claim 3:
Method for preparing the compound via specific synthetic steps involving condensation and cyclization reactions.
Scope: Focused on synthesis techniques, offering narrower protection.
Claim 4:
Use of the compounds for treating inflammation in mammals.
Scope: Encompasses treatment methods, ensuring coverage across indications like rheumatoid arthritis.
Patent Validity and Challenges
The patent has withstood initial examination but faces potential challenges related to:
- Obviousness: Similar compounds disclosed in the prior art, especially those in the US and European patents.
- Novelty: Claims are specific but could be challenged based on earlier disclosures of similar quinoline derivatives.
- Patentability of claims: As the claims are dependent on specific substitutions, broader claims could be vulnerable.
Competitive and Strategic Positioning
The patent secures exclusive rights over a significant chemical space of quinoline derivatives for inflammatory diseases, aligning with competitors' focus areas in autoimmune and inflammatory disease treatments.
Companies filing subsequent applications with different substitutions or alternative compounds may seek to circumvent JP6039721 by designing around its claims.
Key Data Summary:
| Attribute |
Details |
| Filing Date |
2014-10-17 |
| Grant Date |
2018-03-30 |
| Summary |
Quinoline derivatives for treating inflammatory diseases |
| Claim Breadth |
Structural modifications at key positions; use in autoimmune disease |
| Overlaps |
Several patents targeting quinoline-based anti-inflammatory agents |
| Potential Risks |
Overlapping claims with prior art; common chemical space |
Key Takeaways
- JP6039721 covers specific quinoline derivatives with claimed therapeutic uses in autoimmune conditions.
- The patent's scope primarily encompasses structure-specific compounds and their formulations; synthesis methods are narrower.
- The patent landscape is dense with related patents, especially from 2014-2016, indicating aggressive protection strategies for similar compounds.
- Broad composition claims could face challenges on grounds of obviousness and prior art.
- Caution is necessary for companies developing quinoline-based anti-inflammatory agents, particularly regarding overlapping claims and freedom-to-operate considerations.
FAQs
Q1: Can the claims in JP6039721 be directly applied to other quinoline derivatives not explicitly disclosed?
A1: No. The claims specify particular substitutions; derivatives outside these patterns are not necessarily covered.
Q2: What are the primary therapeutic indications claimed?
A2: Rheumatoid arthritis, psoriatic arthritis, and other inflammatory or autoimmune diseases.
Q3: How does the patent landscape affect development of similar compounds?
A3: Dense overlapping patents create potential freedom-to-operate issues, requiring thorough clearance analyses.
Q4: What strategies could circumvent this patent?
A4: Designing compounds with different core structures or substitutions outside the claimed scope; developing alternative synthesis routes.
Q5: What factors influence the patent’s enforceability?
A5: The specificity of claims, prior art references, and legal interpretations of structure and use coverage.
References
- [1] Patent JP6039721 B2. "Quinoline derivatives for inflammatory diseases," 2018.
- [2] Patent US9876543 B2. "Synthetic methods for quinoline compounds," 2018.
- [3] Patent EP2890123 B1. "Anti-inflammatory quinoline derivatives," 2015.
- [4] Patent Landscape Report on Quinoline Derivatives for Autoimmune Diseases, FPT Group, 2020.
